|
AU1331892A
(en)
|
1991-02-01 |
1992-09-07 |
Coulter Corporation |
Method of producing f(ab')2 fragments of immunoglobulins
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
ATE239041T1
(de)
|
1996-02-09 |
2003-05-15 |
Basf Ag |
Humane antikörper welche an humanen tnfalpha binden
|
|
ATE370961T1
(de)
|
1998-05-06 |
2007-09-15 |
Genentech Inc |
Reinigung von antikörpern durch ionenaustauschchromatographie
|
|
US20140186361A1
(en)
|
2012-09-07 |
2014-07-03 |
Coherus Biosciences, Inc. |
Stable Aqueous Formulations of Adalimumab
|
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
US20040131614A1
(en)
|
2002-07-19 |
2004-07-08 |
Abbott Biotechnology Ltd. |
Treatment of pulmonary disorders using TNFalpha inhibitor
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
US8227241B2
(en)
|
2004-03-12 |
2012-07-24 |
Unigene Laboratories, Inc. |
Bacterial host cell for the direct expression of peptides
|
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
艾伯維生物技術有限責任公司 |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
EP1865986B1
(en)
|
2005-03-08 |
2016-02-17 |
Pfizer Products Inc. |
Anti-ctla-4 antibody compositions
|
|
JP5757495B2
(ja)
|
2005-05-16 |
2015-07-29 |
アッヴィ バイオテクノロジー リミテッド |
びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
|
|
ATE515566T1
(de)
|
2005-05-26 |
2011-07-15 |
Cytos Biotechnology Ag |
Skalierbares fermentationsverfahren
|
|
EP1891110A2
(en)
|
2005-06-07 |
2008-02-27 |
Esbatech AG |
STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
AR058140A1
(es)
|
2005-10-24 |
2008-01-23 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
|
TW201337266A
(zh)
|
2005-11-01 |
2013-09-16 |
Abbott Biotech Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
|
CN102391358B
(zh)
|
2006-04-05 |
2016-08-10 |
艾伯维生物技术有限公司 |
抗体纯化
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
|
EP2666478A3
(en)
|
2006-04-10 |
2014-10-22 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of psoriasis
|
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
|
US20080118496A1
(en)
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
WO2007120626A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of ankylosing spondylitis
|
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
US20080311043A1
(en)
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
|
CN103316402A
(zh)
|
2006-06-30 |
2013-09-25 |
艾伯维生物技术有限公司 |
自动注射装置
|
|
JP5437633B2
(ja)
|
2006-09-11 |
2014-03-12 |
株式会社 免疫生物研究所 |
モノクローナル抗体およびその用途
|
|
EP2500416A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
|
TW201516149A
(zh)
|
2006-09-13 |
2015-05-01 |
Abbvie Inc |
細胞培養改良
|
|
EP2684895A1
(en)
|
2006-10-27 |
2014-01-15 |
AbbVie Biotechnology Ltd |
Crystalline anti-hTNFalpha antibodies
|
|
WO2008121324A2
(en)
|
2007-03-30 |
2008-10-09 |
Abbott Laboratories |
Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
|
|
WO2008136398A1
(ja)
|
2007-04-26 |
2008-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
高濃度アミノ酸含有培地を用いた細胞の培養方法
|
|
EP2165194A4
(en)
|
2007-05-31 |
2010-09-08 |
Abbott Lab |
BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
|
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
|
UA107557C2
(xx)
*
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
MX2010001488A
(es)
|
2007-08-08 |
2010-03-01 |
Abbott Lab |
Composiciones y metodos para cristalizar anticuerpos.
|
|
AU2008304111B2
(en)
|
2007-09-27 |
2014-04-24 |
Amgen Inc. |
Pharmaceutical formulations
|
|
US8420081B2
(en)
|
2007-11-30 |
2013-04-16 |
Abbvie, Inc. |
Antibody formulations and methods of making same
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
WO2009073805A2
(en)
|
2007-12-04 |
2009-06-11 |
Verdezyne, Inc. |
Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
|
|
ATE460666T1
(de)
|
2008-01-15 |
2010-03-15 |
Univ Utrecht Holding Bv |
Verfahren zur bestimmung der aminosäurensequenz von peptiden
|
|
ES2579231T3
(es)
|
2008-01-15 |
2016-08-08 |
Abbvie Inc |
Vectores de expresión de mamíferos mejorados y usos de los mismos
|
|
SG2013054218A
(en)
|
2008-01-15 |
2014-10-30 |
Abbott Gmbh & Co Kg |
Powdered protein compositions and methods of making same
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
MX2010010503A
(es)
|
2008-03-24 |
2010-11-09 |
Abbott Biotech Ltd |
Metodos y composiciones para tratar perdida osea.
|
|
PL2282773T3
(pl)
|
2008-05-02 |
2014-08-29 |
Seattle Genetics Inc |
Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
|
|
CN104974251A
(zh)
|
2008-10-20 |
2015-10-14 |
Abbvie公司 |
在抗体纯化过程中的病毒灭活
|
|
CN102257004A
(zh)
|
2008-10-20 |
2011-11-23 |
雅培制药有限公司 |
与il-12结合的抗体及其纯化方法
|
|
CA2932207A1
(en)
|
2008-10-20 |
2010-12-09 |
Abbvie Inc. |
Isolation and purification of antibodies using protein a affinity chromatography
|
|
RU2481824C2
(ru)
|
2008-10-29 |
2013-05-20 |
Аблинкс Н.В |
Препараты однодоменных антигенсвязывающих молекул
|
|
MX2011005672A
(es)
|
2008-11-28 |
2011-06-20 |
Abbott Lab |
Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
|
|
CN102348979A
(zh)
|
2009-03-09 |
2012-02-08 |
乔治亚大学研究基金公司 |
胃癌诊断用蛋白标记的鉴定
|
|
US20100278822A1
(en)
|
2009-05-04 |
2010-11-04 |
Abbott Biotechnology, Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
DK2808393T3
(en)
|
2009-06-02 |
2018-03-12 |
Regeneron Pharma |
Cells insufficient for fucosylation
|
|
WO2010141855A1
(en)
|
2009-06-05 |
2010-12-09 |
Momenta Pharmaceuticals, Inc. |
Methods of modulating fucosylation of glycoproteins
|
|
WO2011028962A1
(en)
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody coformulations
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
SI3409289T1
(sl)
|
2010-02-26 |
2020-12-31 |
Novo Nordisk A/S |
Stabilni sestavki, ki vsebujejo protitelo
|
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
|
SG10201503899SA
(en)
|
2010-05-18 |
2015-06-29 |
Abbvie Inc |
Apparatus And Process Of Purification Of Proteins
|
|
HRP20171095T4
(hr)
|
2010-05-25 |
2022-07-22 |
F. Hoffmann - La Roche Ag |
Postupci pročišćavanja polipeptida
|
|
MX2012014080A
(es)
|
2010-06-03 |
2013-05-01 |
Abbvie Biotechnology Ltd |
Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
|
|
CA2810909A1
(en)
|
2010-09-20 |
2012-03-29 |
Abbvie Inc. |
Purification of antibodies using simulated moving bed chromatography
|
|
US20120258496A1
(en)
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
BR112013008738B1
(pt)
|
2010-10-11 |
2017-12-19 |
Abbvie Bahamas Ltd. |
Method for purification of a protein
|
|
TWI603739B
(zh)
|
2010-11-11 |
2017-11-01 |
艾伯維生物技術有限責任公司 |
具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
|
|
MY163081A
(en)
|
2010-12-28 |
2017-08-15 |
Chugai Pharmaceutical Co Ltd |
Animal cell culturing method
|
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
SI2726600T1
(sl)
|
2011-07-01 |
2017-07-31 |
Amgen Inc. |
Sesalska celična kultura
|
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
|
CA2850668A1
(en)
|
2011-10-04 |
2013-04-11 |
Expression Pathology, Inc. |
Srm/mrm assay for the ephrin type-a receptor 2 protein
|
|
AU2012328921B2
(en)
|
2011-10-24 |
2017-05-11 |
Abbvie Inc. |
Immunobinders directed against TNF
|
|
US20140288278A1
(en)
|
2011-10-31 |
2014-09-25 |
Joseph Nti-Gyabaah |
Chromatography process for resolving heterogeneous antibody aggregates
|
|
WO2013114164A1
(en)
|
2012-01-30 |
2013-08-08 |
Dr. Reddy's Laboratories Limited |
Method for obtaining glycoprotein composition with increased afucosylation content
|
|
WO2013114165A1
(en)
|
2012-01-30 |
2013-08-08 |
Dr Reddy's Laboratories Limited |
Process of obtaining glycoprotein composition with increased afucosylation content
|
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
EP2863951A1
(en)
|
2012-06-12 |
2015-04-29 |
Boehringer Ingelheim International GmbH |
Pharmaceutical formulation for a therapeutic antibody
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
JP5874587B2
(ja)
|
2012-09-10 |
2016-03-02 |
株式会社島津製作所 |
アミノ酸配列解析方法及び装置
|
|
NO2760138T3
(enExample)
|
2012-10-01 |
2018-08-04 |
|
|
|
EP2906683B1
(en)
|
2012-10-15 |
2017-05-31 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
|
US9844594B2
(en)
|
2012-12-18 |
2017-12-19 |
Merck Sharp & Dohme Corp. |
Liquid formulations for an anti-TNF α antibody
|
|
CN105007896B
(zh)
|
2012-12-28 |
2019-04-09 |
雅培心血管系统公司 |
包含抗体的治疗组合物
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
US20140271633A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Mammalian cell culture performance through surfactant supplementation of feed media
|
|
US9217168B2
(en)
|
2013-03-14 |
2015-12-22 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
|
BR112015017307A2
(pt)
|
2013-03-14 |
2017-11-21 |
Abbvie Inc |
composições de espécies com baixa acidez e métodos para produção e uso das mesmas
|
|
EP2990485B1
(en)
|
2013-04-25 |
2019-09-11 |
Kaneka Corporation |
Fd chain gene or l chain gene each capable of increasing secretion amount of fab-type antibody
|
|
WO2014182658A1
(en)
|
2013-05-06 |
2014-11-13 |
Abbvie Inc. |
Compositions for cell culture and methods of using the same
|
|
TWI596107B
(zh)
|
2013-06-25 |
2017-08-21 |
卡地拉保健有限公司 |
單株抗體之新穎純化方法
|
|
EP3114476A4
(en)
|
2013-10-03 |
2017-11-01 |
Bioanalytix, Inc. |
Mass spectrometry-based method for identifying and maintaining quality control factors during the development and manufacture of a biologic
|
|
AU2014337263B2
(en)
|
2013-10-16 |
2019-12-12 |
Outlook Therapeutics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
WO2015140700A1
(en)
|
2014-03-19 |
2015-09-24 |
Dr. Reddy's Laboratories Limited |
Cell culture process
|
|
PL2946765T3
(pl)
*
|
2014-05-23 |
2017-08-31 |
Ares Trading S.A. |
Ciekła kompozycja farmaceutyczna
|
|
HUP1400510A1
(hu)
*
|
2014-10-28 |
2016-05-30 |
Richter Gedeon Nyrt |
Gyógyászati TNFalfa ellenes antitest készítmény
|
|
CN105044222B
(zh)
|
2014-12-19 |
2017-09-12 |
浙江辉肽生命健康科技有限公司 |
生物活性多肽的分析测试和鉴定方法
|
|
EP3247718B1
(en)
|
2015-01-21 |
2021-09-01 |
Outlook Therapeutics, Inc. |
Modulation of charge variants in a monoclonal antibody composition
|
|
EP3250598A1
(en)
*
|
2015-01-28 |
2017-12-06 |
Mabxience S.A. |
Pharmaceutical formulations for anti-tnf-alpha antibodies
|
|
CN105779394B
(zh)
|
2015-03-20 |
2020-03-24 |
广东东阳光药业有限公司 |
一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法
|
|
JP6674028B2
(ja)
|
2016-01-06 |
2020-04-01 |
アウトルック セラピューティクス，インコーポレイティド |
モノクローナル抗体組成物中のアフコシル化種の調節
|
|
AU2017206012A1
(en)
|
2016-01-06 |
2018-07-26 |
Outlook Therapeutics, Inc. |
Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
|
|
EP3411401A1
(en)
|
2016-02-03 |
2018-12-12 |
Oncobiologics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
MX2018009339A
(es)
|
2016-02-04 |
2019-01-10 |
Oncobiologics Inc |
Métodos para la identificación y análisis de secuencias de aminoácidos de las proteínas.
|